Why your manufacturing floor is your greatest compliance risk – and opportunity
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to …
Post
-
-
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
A patient who developed multidrug-resistant E. coli following a transplant has recovered following treatment with an investigational clustered regularly interspaced …
-
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the …
-
Epicrispr, Vaderis secure pivotal study funding for rare disease assets
Two biotech companies, Epicrispr Biotechnologies and Vaderis Therapeutics, have secured fresh capital to take their rare disease assets to late-stage …
-
Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial …
-
Alfasigma signs agreement to acquire Nordic Group
Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach …
-
Commercialising drugs in Europe: Lean models for first-time launchers
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% - …
-
Trump signs order that nearly halves childhood immunisation coverage
President Donald Trump has signed an executive order (EO) that significantly narrows the recommendations for paediatric immunisation, marking the latest …
-
Health tech’s role in obesity to expand beyond a ‘nice-to-have’
In recent years, there has been a sharp focus on treating obesity and its associated comorbidities, as the World Health …
-
UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Eli Lilly’s oral weight loss therapy, Foundayo (orforglipron), intensifying …
-
BMS banks on Texas for $2.3bn multi-modal manufacturing facility
Bristol Myers Squibb (BMS) has chosen Texas as the home to its new $2.3bn manufacturing facility – marking another significant …
-
BeOne and Revolution Medicines partner for oncology therapies
BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies. The deal includes joint …
-
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals has signed a definitive agreement to purchase Actio Biosciences in a deal that includes an upfront payment of …
-
Lyophilisation is growing in pharma, but technical challenges persist
Lyophilisation, or freeze drying, is the process in which a liquid drug is converted into a stable powder via sublimation, …
-
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
The Swedish Orphan Biovitrum, or Sobi, has inked a licensing deal worth up to $580m with Innate Pharma for its …
